CervoMed (CRVO) Fundamental Analysis: Revenue, Earnings & Valuation

3.94 / 10

Netural

Fundamental rating is Neutral with a 3.9/10 score, indicating challenging fundamentals. Revenue‑MV, Profit‑MV, Cash‑MV, inventory turnover and profit margins are modestly bullish, while Asset‑MV and tax‑to‑profit ratios are weak, leading to a defensive outlook.

Analysis Checks(7/10)

Revenue-MV

Value-7.44

Score2/3

Weight21.75%

1M Return8.05%

Inventory turnover ratio

Value106.57

Score3/3

Weight18.82%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.99%

1M Return1.67%

Profit-MV

Value0.68

Score2/3

Weight17.70%

1M Return6.36%

Income tax / Total profit (%)

Value22.35

Score1/3

Weight0.43%

1M Return0.21%

Current assets turnover ratio

Value0.12

Score1/3

Weight-0.39%

1M Return-0.17%

Fixed assets turnover ratio

Value9771.06

Score3/3

Weight3.75%

1M Return1.76%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight9.35%

1M Return4.08%

Asset-MV

Value-0.55

Score0/3

Weight7.26%

1M Return2.73%

Cash-MV

Value0.03

Score2/3

Weight17.34%

1M Return6.19%

Is CRVO undervalued or overvalued?

CRVO scores 3.94/10 on fundamentals and holds a Fair valuation at present. Backed by its -93.92% ROE, -673.06% net margin, -1.35 P/E ratio, 1.99 P/B ratio, and -47.52% earnings growth, these metrics solidify its Netural investment rating.